Back to top
more

Alexion Pharmaceuticals, Inc. (ALXN)

(Delayed Data from NSDQ)

$136.69 USD

136.69
978,618

+3.56 (2.67%)

Updated May 3, 2019 04:00 PM ET

After-Market: $136.70 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Alexion Pharmaceuticals (ALXN) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALXN vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

ALXN vs. TECH: Which Stock Is the Better Value Option?

AbbVie (ABBV) Venclexta Gets Breakthrough Therapy Tag for MDS

by Zacks Equity Research

The FDA grants a Breakthrough Therapy designation to AbbVie's (ABBV) Venclexta in combination with azacitidine for treating adult patients with higher risk myelodysplastic syndrome.

Bayer's (BAYRY) Parkinson's Disease Therapy Gets Fast Track Tag

by Zacks Equity Research

The FDA grants a Fast Track status to Bayer's (BAYRY) DA01 cell therapy which is being developed for the treatment of Parkinson's disease.

Sanghamitra Saha headshot

Moderna Soars on Inclusion to S&P 500: ETFs in Focus

by Sanghamitra Saha

Moderna, known for its success in the COVID-19 vaccine, has entered the big league with its addition to the S&P 500 Index.

Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study

by Zacks Equity Research

Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.

Is a Beat in the Cards for Anthem (ANTM) in Q2 Earnings?

by Zacks Equity Research

Anthem's (ANTM) second-quarter results are likely to benefit on the back of higher premiums coupled with growing Medicaid and Medicare membership, partly offset by escalating costs.

Moderna (MRNA) Set to Join S&P 500 Riding on Vaccine Success

by Zacks Equity Research

Moderna's (MRNA) success with its COVID-19 vaccine, mRNA-1273, continues to drive the stock. The company crosses $100-billion in market capitalization and will join the S&P 500 soon.

Galapagos (GLPG) Falls on Inflammatory Study Data Readout

by Zacks Equity Research

Galapagos (GLPG) announces data from multiple studies evaluating its two inflammatory candidates - GLPG3970 and GLPG3667. Stock down.

Why Alexion Pharmaceuticals (ALXN) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here is Why Growth Investors Should Buy Alexion (ALXN) Now

by Zacks Equity Research

Alexion (ALXN) could produce exceptional returns because of its solid growth attributes.

AstraZeneca (AZN) Gets Clearance in UK for Alexion Acquisition

by Zacks Equity Research

AstraZeneca (AZN) obtains UK Competition and Markets Authority's permission for the impending acquisition of Alexion. The deal is expected to close on Jul 21, 2021.

Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug

by Zacks Equity Research

Biogen partners with InnoCare Pharma for orelabrutinib, a BTK inhibitor with the potential of treating multiple sclerosis. The drug is currently undergoing phase II study.

Alexion (ALXN) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Alexion (ALXN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Kinjel Shah headshot

7 Low Price-to-Book Stocks Worth Buying in July

by Kinjel Shah

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition

by Zacks Equity Research

AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.

ALXN or GMAB: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

ALXN vs. GMAB: Which Stock Is the Better Value Option?

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Biotech Stock Roundup: BIIB's Drug Approval, ALXN Drug Label Expansion & More

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Biogen (BIIB) and bluebird (BLUE), among others.

Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids

by Zacks Equity Research

The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.

Immunovant (IMVT) Reports Narrower-Than-Expected Loss in Q4

by Zacks Equity Research

Immunovant's (IMVT) earnings beat estimates in fourth-quarter fiscal 2021. Focus remains on lead pipeline candidate IMVT-1401. Stock falls.

Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study

by Zacks Equity Research

Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.

Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug

by Zacks Equity Research

Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?

by Zacks Equity Research

Sector ETF report for PBE

Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod

by Zacks Equity Research

The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.